APIE Therapeutics is a start-up BioPharma pioneering an anti-fibrotic small molecule platform. APIE has a portfolio (+800) of novel compounds that selectively target APJ G-coupled receptor to stimulate the angiocrine factors signaling pathway that promotes repair and regeneration of the injured tissue. APIE's initial APT101 clinical candidate is being develop for Systemic Scleroderma (SSc), a rare autoimmune disease characterized by vascular endothelium alterations in single or multi-organ that leads to fibrosis and organ failure. APT101 has demonstrated significant therapeutic effect in lung fibrosis, which is the major cause of early death in SSc patients. Moreover, APT101 drug distribution profile and MOA has the potential to address multi-organ SSc disease progression to change the disease course and survival of SSc patients. APIE is well positioned to reach SSc IND milestone by 1H2023 and launch its clinical trial by 2H2023. APIE Management Team is composed of highly experienced individuals that have come together in pursue of bringing innovative treatments to patients in need.